Lipella Pharmaceuticals Inc. is on the Cruelty-Free Investing usage of animals list because they undertake pre-clinical studies on animals to examine the safety profile of their medications.
The company stated in the following report that they exploit animals for drug testing.
“First, our API has a well-known mechanism of action. Second, published non-clinical studies involving animals, which are described above, demonstrate the potential for significant efficacy in our intended indication and route of administration.” (Page 60) Read the full document
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
Company Website: https://lipella.com